An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
Mesothelin lives on
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
